Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories
Article first published online: 22 NOV 2013
© 2013 Biogen Idec Inc. Haemophilia Published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Volume 20, Issue 2, pages 294–300, March 2014
How to Cite
Sommer, J. M., Moore, N., McGuffie-Valentine, B., Bardan, S., Buyue, Y., Kamphaus, G. D., Konkle, B. A. and Pierce, G. F. (2014), Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia, 20: 294–300. doi: 10.1111/hae.12296
- Issue published online: 18 FEB 2014
- Article first published online: 22 NOV 2013
- Manuscript Accepted: 7 OCT 2013
- UBC-Envision Group
- Biogen Idec
- 4Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays. J Thromb Haemost 2004; 2: 623–8., , , .
- 10Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII). Haemophilia 2009; 15: 779–87., , et al.
- 19Phase 3 Clinical Study of Recombinant Fc Fusion Factor FVIII (rFVIIIFc) Demonstrated Safety, Efficacy, and Improved Pharmacokinetics (A-LONG). Haemophilia 2013; 19: PO104., , et al.
- 24Advate Prescribing Information. Westlake Village, CA: Baxter Healthcare Corporation, 2012.